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Abstract
Botulinum toxin type A (BoNT-A) is used extensively in the neurological setting, most commonly for the 
management of dystonia and spasticity. It is inevitable that female patients who derive a significant benefit 
from botulinum toxin treatment may inadvertently be injected in as-yet undiagnosed pregnancy or may be 
planning to become pregnant.  Following an examination of the evidence for the safety of botulinum toxin in 
pregnancy, physicians and patients should be reassured as to the absence of evidence of harm in case reports 
of botulism and accidental or intentional botulinum toxin injection and the improbability of crossing the 
placenta. Consequently, judgment should be made that acknowledges that when botulinum toxin treatment 
is to continue through pregnancy it should be because this will represent the lesser harm in view of the 
severity of the mother’s symptoms and the physical and psychological harm caused by withholding 
treatment. It is also normally appropriate to reassure patients inadvertently injected.
INTRODUCTION
Botulinum toxin type A (BoNT-A) is used in the treatment of dystonia. The commonest form, cervical 
dystonia, is more frequent in women and many are still of child bearing age[1]; it is inevitable that patients 
on botulinum toxin treatment will from time to time either be planning to become pregnant or may wish to 
be treated while pregnant. In addition to cervical dystonia, the newer indication of BoNT-A for chronic 
migraine – a female predominant disorder – will make this an increasingly common issue,[2] not to mention 
the use of BoNT-A in a wider cosmetic setting. To help the patient make an informed choice we need to 
determine what is known of the risks of botulinum toxin treatment in pregnancy and lactation. 
There are two relevant situations. Firstly, the risks arising from an injection of BoNT-A in a patient who is 
unaware they are pregnant, and secondly the risks of continuing or curtailing treatment in an already 
pregnant patient.
The international regulatory bodies are not proscriptive.  The Medicines and Healthcare products Regulatory 
Agency (MHRA) recommend that caution is exercised when prescribing BoNT-A.[3] All BoNT-A 
preparations are Food and Drug Administration (FDA) category C, which means that there have been 
inadequate studies on the use of BoNT-A in pregnant women,[4] but that studies in animals have shown 
there to be an adverse effect on the foetus.[5,6] Molecules less than 500Da have incomplete transfer across 
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the placenta; botulinum toxin is a large molecule (150kDa) and therefore unlikely to cross the placenta by 
passive diffusion.[7] Active transport across the placenta cannot be excluded.
Despite the caution, there is no definitive evidence that treatment with BoNT-A during pregnancy carries a 
risk. There are a growing number of reports of the outcome of pregnancy following botulism [8,9] or after 
therapeutic injection that have not been attended by evidence of foetal harm.[10-18] Long term follow up of 
the resulting child is usually lacking.  There is no evidence of harm – but absence of evidence is not 
evidence of absence.
Dystonia seriously undermines self-confidence and produces pain, deformity and loss of function. It is 
known that dystonia has an impact on quality of life greater than that seen in conditions considered more 
serious, such as multiple sclerosis and Parkinson’s disease.[19] For those patients who respond to treatment 
of migraine, BoNT-A can be life transforming and the prospect of cessation of treatment may be daunting 
for the patient. In making a judgment, the impact of the untreated disorder must be considered by both 
neurologists and patients.
There is thus insufficient evidence to allow truly informed consent. Despite this however, in a survey of 
physicians using BoNT-A, of the respondents that had injected BoNT-A during pregnancy, half reported 
that they felt either “somewhat” or “very comfortable” injecting during pregnancy.[20] 
The epilepsy pregnancy registries [21,22] provide an excellent model that has provided invaluable insights 
into the relative risks of different anticonvulsants. A similar botulinum toxin in pregnancy register could 
relatively readily provide the evidence that is needed to allow women considering pregnancy, or 
inadvertently exposed to botulinum toxin during pregnancy, to be as fully informed to make decisions on 
their continued treatment.
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